Navigation Links
Everett Laboratories Acquires Quinnova Pharmaceuticals to Diversify U.S. Pharmaceutical Presence
Date:12/16/2013

CHATHAM, N.J. and JAMISON, Pa., Dec. 16, 2013 /PRNewswire/ -- Everett Laboratories, Inc., a privately held specialty pharmaceutical company and a subsidiary of Exeltis, headquartered in Madrid, Spain, today announced that it has acquired Quinnova Pharmaceuticals, Inc. from parent company Amneal Enterprises, LLC.

The acquisition will result in the strategic expansion of Everett into the fast-growing U.S. dermatology market. With the Quinnova acquisition, Everett will increase and diversify its presence in the U.S. specialty pharmaceutical market, poising the Company for accelerated growth in both women's health and dermatology.

As a member of the Exeltis family, the acquisition will allow Quinnova to leverage extensive resources and capabilities in research and development, marketing strategy, intellectual property and business development worldwide.  This broad-based support will enable Quinnova to be positioned to accelerate growth and development of its product portfolio and development pipeline.

Lucas Sigman, Chief Executive Officer of Everett Laboratories, said of the acquisition: "We believe dermatology is a very attractive opportunity for Everett in the U.S. market and after an extensive search, we found Quinnova to be a great organization to help us grow this business. Quinnova offers important synergies for Everett with its innovative and entrepreneurial culture, as well as its dedicated and focused sales team, which is similar to Everett. With strong technology platforms and a robust pipeline of new products, we believe with the addition of Quinnova, Everett will accelerate its growth trajectory and be well positioned to become a market leader in women's health and dermatology in the very near future. In addition, the acquisition provides opportunities for growth for Exeltis by allowing the Company to leverage the Quinnova portfolio of products and technology platform to grow the dermatology business globally."

Jeffrey S. Day, Quinnova's President and CEO, stated, "Everett and Quinnova share similar values, culture and corporate vision, making this transaction a perfect fit for both organizations. I am excited about Quinnova becoming a member of the Exeltis family of aligned companies and what this acquisition represents for everyone at Quinnova Pharmaceuticals as well as to the dermatology marketplace. This acquisition allows Quinnova to accelerate key projects in our commercial operations, complete high-potential R&D projects, build out our robust pipeline, and fulfill the Company's vision for advancing skin and wound care therapeutics for patients." 

About Everett Laboratories:

Everett Laboratories, Inc. is a New Jersey based specialty pharmaceutical company providing essential pharmaceutical and nutritional products for four decades. During the last 20 years, Everett has focused in Women's Health Care, becoming a leader in the Prenatal Vitamin Market driven by its lead brand, Vitafol One. In 2010, Exeltis acquired Everett to expand into the US Women's Healthcare Market. Exeltis will further support these efforts with a robust portfolio consisting of NDA products. For more information, visit www.everettlabs.com.  

About Quinnova Pharmaceuticals:

Quinnova Pharmaceuticals, LLC, is a specialty pharmaceutical company founded on innovative, patent-protected dermal delivery technologies which are utilized to transport safe and effective pharmaceutical ingredients, through the epidermis, in unique, convenient, and cosmetically elegant formulations. Addressing a wide variety of skin conditions, Quinnova's mission is to provide superior treatment solutions and product value to clinicians and patients. For more information, visit www.quinnova.com.


'/>"/>
SOURCE Everett Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
2. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
3. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
6. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
7. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
11. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
Breaking Medicine Technology:
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):